Skip to Main content Skip to Navigation
Journal articles

Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?

Abstract : Thiopurines remain the backbone therapy of inflammatory bowel diseases (IBD). However, these drugs have potential mutagenic and carcinogenic effects, especially when prescribed for a long time. In addition to the increased risk of lymphoma and non-melanoma skin cancer, recent data suggest that risk of myeloid disorder is increased in IBD patients with past exposure to thiopurines. Even if individual risk is low, practitioners who take care of IBD patients should be aware of this potential complication of thiopurines treatment.
Document type :
Journal articles
Complete list of metadata

https://hal.univ-lorraine.fr/hal-01699614
Contributor : Ngere Ul <>
Submitted on : Friday, February 2, 2018 - 3:25:08 PM
Last modification on : Friday, December 11, 2020 - 3:18:23 AM

Identifiers

Citation

Anthony Lopez, Laurent Beaugerie, Laurent Peyrin-Biroulet. Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?. Expert Review of Clinical Immunology, Expert Reviews (formerly Future Drugs), 2014, 10 (12), pp.1563 - 1565. ⟨10.1586/1744666X.2014.977261⟩. ⟨hal-01699614⟩

Share

Metrics

Record views

96